ArticleOpen forum infectious diseases2022

Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY).

Laura L Hammitt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.